How to integrate evidence from patient preference studies into health technology assessment: a critical review and recommendations
暂无分享,去创建一个
[1] K. Marsh,et al. Assessing Patient Preferences in Rare Diseases: Direct Preference Elicitation in the Rare Chronic Kidney Disease, Immunoglobulin A Nephropathy , 2021, The Patient - Patient-Centered Outcomes Research.
[2] S. Simoens,et al. Use of Patient Preferences in Health Technology Assessment: Perspectives of Canadian, Belgian and German HTA Representatives , 2020, The Patient - Patient-Centered Outcomes Research.
[3] I. Huys,et al. An overview of critical decision-points in the medical product lifecycle: Where to include patient preference information in the decision-making process? , 2020, Health policy.
[4] K. Marsh,et al. Health Preference Research in Europe: A Review of Its Use in Marketing Authorization, Reimbursement, and Pricing Decisions-Report of the ISPOR Stated Preference Research Special Interest Group. , 2020, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[5] C. Phelps,et al. Health technology assessment with risk aversion in health. , 2020, Journal of health economics.
[6] J. Bouvy,et al. Use of Patient Preference Studies in HTA Decision Making: A NICE Perspective , 2020, The Patient - Patient-Centered Outcomes Research.
[7] Transcatheter Aortic Valve Implantation in Patients With Severe Aortic Valve Stenosis at Low Surgical Risk: A Health Technology Assessment. , 2020, Ontario health technology assessment series.
[8] Genome-Wide Sequencing for Unexplained Developmental Disabilities or Multiple Congenital Anomalies: A Health Technology Assessment. , 2020, Ontario health technology assessment series.
[9] S. Simoens,et al. Design, Conduct, and Use of Patient Preference Studies in the Medical Product Life Cycle: A Multi-Method Study , 2019, Front. Pharmacol..
[10] F. Gutzwiller,et al. Gathering Structured Patient Insight to Drive the PRO Strategy in COPD: Patient-Centric Drug Development from Theory to Practice , 2019, Advances in Therapy.
[11] J. van Exel,et al. What Is Next for Patient Preferences in Health Technology Assessment? A Systematic Review of the Challenges. , 2019, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[12] M. Bliemer,et al. Are Healthcare Choices Predictable? The Impact of Discrete Choice Experiment Designs and Models. , 2019, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[13] A. Holtorf,et al. Patient Preference Studies During Early Drug Development: Aligning Stakeholders to Ensure Development Plans Meet Patient Needs , 2019, Front. Med..
[14] J. Rose,et al. Valuing injection frequency and other attributes of type 2 diabetes treatments in Australia: a discrete choice experiment , 2018, BMC Health Services Research.
[15] Tommi Tervonen,et al. The Use of MCDA in HTA: Great Potential, but More Effort Needed. , 2017, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[16] F. Johnson,et al. Giving Patients a Meaningful Voice in European Health Technology Assessments: The Role of Health Preference Research , 2017, The Patient - Patient-Centered Outcomes Research.
[17] A. Mühlbacher,et al. The Probabilistic Efficiency Frontier: A Framework for Cost-Effectiveness Analysis in Germany Put into Practice for Hepatitis C Treatment Options. , 2017, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[18] W. Brouwer,et al. Patient and general public preferences for health states: A call to reconsider current guidelines. , 2016, Social Science & Medicine (1967).
[19] P. Vickerman,et al. Parameterising User Uptake in Economic Evaluations: The role of discrete choice experiments , 2016, Health economics.
[20] K. Marsh,et al. Assessing the Value of Healthcare Interventions Using Multi-Criteria Decision Analysis: A Review of the Literature , 2014, PharmacoEconomics.
[21] Anja Schwalm,et al. Choice-based Conjoint Analysis – pilot project to identify , weight , and prioritize multiple attributes in the indication “ hepatitis C ” 1 , 2014 .
[22] M. Ryan,et al. Developing a Preference-Based Glaucoma Utility Index Using a Discrete Choice Experiment , 2007, Optometry and vision science : official publication of the American Academy of Optometry.
[23] Jan Abel Olsen,et al. The role of adaptation to disability and disease in health state valuation: a preliminary normative analysis. , 2002, Social science & medicine.
[24] P. Ubel,et al. Societal value, the person trade-off, and the dilemma of whose values to measure for cost-effectiveness analysis. , 2000, Health economics.